MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis

Patients with NASH, NAS≥4, and F≥2 (Fibro-NASH) are at highest risk for disease progression.➢Patients with Fibro-NASH are targeted for proof-of-concept NASH trials.➢MRI-PDFF and MR elastography are the most common primary and secondary endpoints in NASH trials, respectively.➢To identify Fibro-NASH, the MRI-AST (MAST) score was created based on these MRI techniques.➢The MAST score was proven to …

Continue reading MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis

EDP-305 in patients with #NASH: A phase II double-blind placebo-controlled dose-ranging study

•EDP-305 is an oral farnesoid X receptor (FXR) agonist being developed to treat nonalcoholic steatohepatitis (NASH).•In a randomized, placebo-controlled study, 12-week study, EDP-305 reduced ALT levels and MRI-PDFF•These results support further development of EDP-305 in patients with NASH with longer term studies. ABSTRACTBackground & AimsEDP-305 is an oral farnesoid X receptor (FXR) agonist under development …

Continue reading EDP-305 in patients with #NASH: A phase II double-blind placebo-controlled dose-ranging study

XCR1+ type 1 conventional #dendritic cells drive liver pathology in non-alcoholic #steatohepatitis

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are prevalent liver conditions that underlie the development of life-threatening cirrhosis, liver failure and liver cancer. Chronic necro-inflammation is a critical factor in development of NASH, yet the cellular and molecular mechanisms of immune dysregulation in this disease are poorly understood. Here, using single-cell transcriptomic analysis, …

Continue reading XCR1+ type 1 conventional #dendritic cells drive liver pathology in non-alcoholic #steatohepatitis

#Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic #Steatohepatitis

We aimed to investigate the mortality and hospital utilization outcomes of hospitalized nonalcoholic steatohepatitis (NASH) patients with and without kidney failure in a nationwide cohort.. ..The overall sample included 7,135,090 patients. Among 6855 patients admitted for NASH, 598 or 8.7% had comorbid kidney failure. After multivariate regression analysis, NASH patients with renal failure had increased …

Continue reading #Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic #Steatohepatitis

A Placebo-Controlled Trial of Subcutaneous #Semaglutide in Nonalcoholic #Steatohepatitis

Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known.. ..In total, 320 patients (of whom 230 had stage F2 or F3 fibrosis) were randomly assigned to …

Continue reading A Placebo-Controlled Trial of Subcutaneous #Semaglutide in Nonalcoholic #Steatohepatitis